Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson disease

European Journal of Neurology

Volumn 16, Issue 2, 2009, Pages 174-182

  Sawada, H ^a   Oeda, T ^a   Yamamoto, K ^a   Kitagawa, N ^a   Mizuta, E ^a   Hosokawa, R ^b   Ohba, M ^b   Nishio, R ^b   Yamakawa, K ^a,b   Takeuchi, H ^a,b   Shimohama, S ^b   Takahashi, R ^b   Kawamura, T ^c  

^a UTANO NATIONAL HOSPITAL   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Norepinephrine; Preclinical diagnosis; ROC curve; Sympathetic nerve

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123;

AGED; AREA UNDER THE CURVE; ARTICLE; BRAIN SCINTISCANNING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE DURATION; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG UPTAKE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; ROC CURVE; SENSITIVITY AND SPECIFICITY;

3-IODOBENZYLGUANIDINE; CROSS-SECTIONAL STUDIES; HUMANS; MYOCARDIAL PERFUSION IMAGING; PARKINSON DISEASE; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 58349095855     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2008.02372.x     Document Type: Article

References (26)

1. Spiegel J, Mollers MO, Jost WH, et al. FP-CIT and MIBG scintigraphy in early Parkinson's disease. Movement Disorders 2005 20 : 552 561.
2. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Annals of Neurology 1995 38 : 589 598.
3. Brooks DJ, Playford ED, Ibanez V, et al. Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology 1992 42 : 1554 1560.
4. Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Movement Disorders 2003 18 : 1415 1423.
5. Mitsui J, Saito Y, Momose T, et al. Pathology of the sympathetic nervous system corresponding to the decreased cardiac uptake in 123I- metaiodobenzylguanidine (MIBG) scintigraphy in a patient with Parkinson disease. Journal of the Neurological Sciences 2006 243 : 101 104.
6. Orimo S, Oka T, Miura H, et al. Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy. Journal of Neurology, Neurosurgery and Psychiatry 2002 73 : 776 777.
7. Iwanaga K, Wakabayashi K, Yoshimoto M, et al. Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology 1999 52 : 1269 1271.
8. Orimo S, Amino T, Itoh Y, et al. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathologica (Berlin) 2005 109 : 583 588.
9. Goldstein DS, Holmes C, Li ST, Bruce S, Metman LV, Cannon RO, 3rd. Cardiac sympathetic denervation in Parkinson disease. Annals of Internal Medicine 2000 133 : 338 347.
10. Goldstein DS. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurology 2003 2 : 669 676.
11. Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 2005 76 : 249 251.
12. Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H. (123)I- metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 1999 67 : 189 194.
13. Yoshita M. Cardiac uptake of [123I]MIBG separates PD from multiple system atrophy. Neurology 2000 54 : 1877 1878.
14. Takatsu H, Nagashima K, Murase M, et al. Differentiating Parkinson disease from multiple-system atrophy by measuring cardiac iodine-123 metaiodobenzylguanidine accumulation. JAMA 2000 284 : 44 45.
15. Druschky A, Hilz MJ, Platsch G, et al. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. Journal of the Neurological Sciences 2000 175 : 3 12.
16. Orimo S, Takahashi A, Uchihara T, et al. Degeneration of cardiac sympathetic nerve begins in the early disase process of Parkinson's disease. Brain Pathology 2007 17 : 24 30.
17. Gerlach M, Hendrich A, Hueber R, et al. Early detection of Parkinson's disease: unmet needs. Neuro-Degenerative Diseases 2008 5 : 137 139.
18. Daniel SE, Lees AJ. Parkinson's Disease Society Brain Bank, London: overview and research. Journal of Neural Transmission. Supplementum 1993 39 : 165 172.
19. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986 1 : 307 310.
20. Sawada H, Yamakawa K, Yamakado H, et al. Cocaine and phenylephrine eye drop test for Parkinson disease. JAMA 2005 293 : 932 934.
21. Hamada K, Hirayama M, Watanabe H, et al. Onset age and severity of motor impairment are associated with reduction of myocardial 123I-MIBG uptake in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 2003 74 : 423 426.
22. Singleton A, Gwinn-Hardy K, Sharabi Y, et al. Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication. Brain 2004 127 : 768 772.
23. Singleton AB, Farrer M, Johnson J, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003 302 : 841.
24. Orimo S, Amino T, Yokochi M, et al. Preserved cardiac sympathetic nerve accounts for normal cardiac uptake of MIBG in PARK2. Movement Disorders 2005 20 : 1350 1353.
25. Quattrone A, Bagnato A, Annesi G, et al. Myocardial 123metaiodobenzylguanidine uptake in genetic Parkinson's disease. Movement Disorders 2008 23 : 21 27.
26. Li ST, Dendi R, Holmes C, Goldstein DS. Progressive loss of cardiac sympathetic innervation in Parkinson's disease. Annals of Neurology 2002 52 : 220 223.